News

Maternal RSV vaccination and nirsevimab were linked to lower infection rates and reduced severity in infants younger than 6 months.

Large trial finds balanced fluids and saline yield similar outcomes in pediatric septic shock, reinforcing flexible resuscitation practices.

Natasha Wade, PhD, highlights longitudinal data showing that adolescent cannabis exposure may blunt neurocognitive development over time.

MMR coverage remained below herd immunity 20 months after an Ohio outbreak, with minimal gains and persistent disparities in children.

Data show children in disaster-displaced households have greater mental health needs but are less likely to receive complete care vs nondisplaced peers.

The FDA approved lunsotogene parvec-cwha as the first gene therapy for genetic hearing loss caused by biallelic OTOF variants.

Fewer pediatric lung transplants are expected worldwide because of advances in cystic fibrosis therapies, but remaining cases are becoming more complex.

The FDA approved dupilumab for children aged 2 to 11 years with chronic spontaneous urticaria, making it the first biologic for young pediatric CSU patients.

FDA expands teplizumab to children aged ≥1 year with stage 2 T1D, enabling earlier intervention to delay progression to insulin dependence.

FDA expands teplizumab (Tzeld) use to children as young as 1 year with stage 2 type 1 diabetes, aiming to delay progression to clinical disease.

In a longitudinal pediatric cohort, elexacaftor/tezacaftor/ivacaftor was associated with increased vitamin D levels and altered vitamin A supplementation response.

Real-world data show pediatric hidradenitis suppurativa treatment relies on antibiotics, with delayed escalation and demographic differences in timing.

New findings highlight elevated secondary cancer risks in adolescent and young adult survivors, underscoring the need for treatment-specific screening strategies.

Marisol Betensky, MD, outlines how dynamic risk evaluation and innovative trial designs can improve anticoagulation decision-making in pediatric VTE care.

A pilot study finds diverse arthritis patterns and high metabolic comorbidity burden in idradenitis suppurativa, with IL-17 inhibitors showing improved outcomes.

Marisol Betensky, MD outlines how institutions can implement risk-stratified guidelines while balancing thrombosis prevention, bleeding risk, and limited evidence.

Mary Pilarz, MD, highlights how allowing families to initiate interpreter use in the PICU boosts utilization and may improve communication equity.

Get caught up with Contemporary Pediatrics. This list helps you navigate our top stories from the week, all in one place.

Findings by Conall Watson, PhD, MSc, highlight that maternal RSV vaccination significantly reduces infant hospitalizations—even when given late in pregnancy.

A nationwide analysis of nearly 300,000 infants found that maternal RSV vaccination reduced severe infant hospitalizations by over 80%.

Jennifer Dantzer, MD, discusses how environmental and genetic factors and clinical features shape the diagnosis and management of seasonal allergies in children.

New evidence using sibling-matched analyses suggests no meaningful association between prenatal acetaminophen use and autism.

Henry Xiang, MD, PhD, highlights the importance of thorough follow-up and family resilience in managing mental health outcomes after traumatic brain injury.

A review suggests that early use of topical calcineurin inhibitors, corticosteroids, and phototherapy can achieve moderate repigmentation in segmental vitiligo.

The FDA has approved landiolol for patients younger than 18 years with supraventricular tachycardia, expanding access.

The FDA will review a supplemental application for delgocitinib cream in patients aged 12 to 17 years, supported by phase 3 data showing improved outcomes.

Mary Beth Howard, MD, MSc, says rising injury rates among young adolescents reflect a mismatch among rider maturity, high-speed devices, and unsafe riding environments.

Adolescent and young adult cancer survivors face a 2-fold increased risk of developing new primary malignancies, with persisting risk.